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ABSTRACT

COMPUTATIONAL LIGAND-BASED CNS THERAPEUTIC DESIGN:
THE SEARCH FOR NOVEL-SCAFFOLD NOREPINEPHRINE
TRANSPORTER INHIBITORS

By
Anna Chaly
December 2012

Thesis supervised by Christopher K. Surratt
Monoamine transporter (MAT) proteins are responsible for regulating cellular
signal transduction through control of neurotransmitter reuptake in the synapse, and are
therefore relevant to diseases including addiction, psychosis, anxiety and depression.
MATs, specifically the serotonin transporter (SERT or 5-HTT), norepinephrine
transporter (NET), and dopamine transporter (DAT), serve as the principal targets for
antidepressant drugs, such as SSRIs (selective serotonin reuptake inhibitors), NRIs
(norepinephrine reuptake inhibitors) and TCAs (tricyclic antidepressants), as well as
psychostimulant drugs of abuse such as cocaine and the amphetamines. Due to a lack of
crystallographic MAT data, it is unclear as to which of two MAT protein ligand binding
sites these drugs bind, hindering knowledge of the specific binding modes of MAT
ligands. In this study an in silico pharmacophore model was created using a ligand-based
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method aimed at drug screening for the ability to specifically inhibit NET, using
Molecular Operating Environment software.

A group of four structurally-diverse

compounds with high NET binding affinities comprised the training set used to generate
the model. A test set, which included ten compounds with a range of known NET
affinities, served in the validation of the model. The constructed pharmacophore model
selected all high affinity NET inhibitors and one relatively inactive compound from the
test set. Following model validation, the ZINC small molecule structural database was
virtually screened to identify novel MAT inhibitor candidates. ―Hit‖ compounds were
ranked by an overlay score, which calculated how well novel compounds aligned to the
original training set alignment.

Six top-ranking compounds were purchased and

evaluated via in vitro pharmacology to determine the binding affinity at the MATs.
Although no significant inhibition was observed at the MATs, compound AC-1 showed a
15% inhibition at the DAT in radioligand binding assays. This result suggests that with
further refinement of key pharmacophore features or alteration of the AC-1 structure,
more potent MAT inhibitors could be discovered. Pharmacophore-based drug design has
become one of the most important tools in drug discovery.

Using the molecular

modeling approaches described in this study, it is possible to rationally design novel and
more selective central nervous system drugs.
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Chapter 1. Introduction

1.1 Statement of the Problem
Mental health illnesses are associated with human suffering, social alienation,
disability and poor quality of life. One of the most prevalent and burdening public health
problems is major depressive disorder (MDD).

According to the World Health

Organization (WHO), depression will be the second most debilitating illness next to heart
disease by the year 2020 (Lin et al., 2011). MDD is one of the most investigated diseases
by disciplines including neuropharmacology and genetics, and believed to be a
combination of hereditary, environmental and developmental factors (Mill and Petronis,
2007). As defined in the DSM-IV, MDD is characterized by periods of depressed mood
lasting for more than two weeks, accompanied by some or all of the following symptoms:
hopelessness, worthlessness, disturbed appetite, weight gain or loss, disturbed sleep
rhythm (insomnia or hypersomnia), reduced concentration, psychomotor agitation or
retardation and recurrent suicidal thoughts (Mill and Petronis, 2007). However, the
molecular mechanisms underlying depression are not fully understood. Studying the
interaction between drugs and their targets, and thereby developing more effective
treatments are the primary goals of research in this study. New treatment options are
crucial to not only reducing the number of people living with such conditions, but to treat
the substantial population that is either resistant to existing pharmacotherapies or cannot
tolerate their adverse effects.
There are currently a variety of options to treat depressed patients, including
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psychotherapy, electroconvulsive therapy, light therapy and pharmacotherapy with
antidepressants (Haenisch and Bonisch, 2011). Regarding the latter, almost all clinically
used antidepressants were developed after the chance discovery in the 1950s that the
tricyclic compound imipramine (Azima and Vispo, 1958; Kuhn, 1958) and the
antituberculosis drug iproniazid were effective in treating depression. Both drugs elevate
extracellular monoamine levels by either inhibiting the neuronal serotonin and/or
norepinephrine transporters (Brown and Gershon, 1993; Nemeroff and Owens, 2002)
(imipramine and its active metabolite desipramine) or by blocking the enzyme
monoamine oxidase (MAO) (iproniazid) (Haenisch and Bonisch, 2011).
Based on the mechanism of action of these drugs, it is believed that abnormal
monoaminergic neurotransmission in the brain is present in depressed patients. However,
it remains unknown why it takes between one and six weeks for antidepressant drugs to
exert their clinical effects (Duman and Monteggia, 2006). One possible explanation for
the delayed onset of antidepressant action is the requirement for neuronal adaptive
mechanisms such as postsynaptic receptor downregulation (Haenisch and Bonisch,
2011). The latency in the onset of antidepressant action is still a problem in the therapy of
MDD since depressive states are often associated with a high risk of committing suicide.
Furthermore, only about 50% of patients with MDD show full remission while receiving
currently available antidepressants (Haenisch and Bonisch, 2011) underscoring the
necessity to find more effective pharmacological treatments for depression and related
conditions.

2

1.2 Monoamine Transporters (MATs)

1.2.1 MAT Structure
The monoamine transporters belong to the SLC6 family of solute carriers of sodium
/ chloride coupled transporters (Kristensen et al., 2011). The SLC6 family is among the
largest of the SLC families, containing 20 genes that encode a group of highly similar
transporter proteins, including those for dopamine (DAT; SLC6A3), serotonin [5hydroxytryptamine (5-HT); SERT; SLC6A4] and norepinephrine (NET; SLC6A2) (Chen
et al., 2004; Hoglund et al., 2005). All SLC6 neurotransmitter transporters are expressed
in the central nervous system (CNS), where their primary physiological function is
neurotransmitter homeostasis (Macdougall and Griffith, 2008).
Different designations for the SLC family are often used, such as the
―neurotransmitter:sodium symporter (NSS),‖ the ―sodium-neurotransmitter symporter
family,‖ or the ―Na/Cl neurotransmitter transporter‖ family (Nelson, 1998; Beuming et
al., 2006). These proteins transport amino acids and their derivatives into cells, using the
electrochemical membrane potential difference of sodium as the energy source. The role
of chlorine in the transport process is not fully understood, but for most MATs, one or
more chlorine ions are hypothesized to be cotransported with sodium and the substrate
(Kristensen, et al., 2011).
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1.2.2 MAT Inhibitors
MAT inhibitors (e.g., GBR-12909, mazindol, fluoxetine, paroxetine, reboxetine,
amoxapine, desipramine, imipramine, bupropion and nisoxetine) have been developed to
treat MDD, psychostimulant dependence, addiction and abuse, attention-deficit
hyperactivity disorder (ADHD), anxiety disorders, mood disorders, personality disorders,
psychosexual disorders, schizophrenia, eating disorders, premenstrual dysphoria,
Parkinson‘s disease, Alzheimer‘s disease, bipolar disorder, chronic pain, migraine,
epilepsy, multiple sclerosis, stroke, trauma, mania, obsessive- compulsive disorder,
obesity and narcolepsy (J. Zhou, 2004). Tricyclic antidepressants (TCAs), including
imipramine and clomipramine, were developed in the 1950s as the first generation of
monoamine transporter drugs. The structure of the TCAs is conserved in that there is a
tricyclic system containing a cycloheptane ring flanked by two phenyl moieties. The
central ring is substituted with an aminopropyl chain, with the amino group being monoor dimethyl substiteted (Andersen et al., 2009). However, the TCAs have shown to act
on a variety of receptors (Gillman, 2007), resulting in major adverse physiological
effects.

1.2.3 MAT Inhibitor Selectivity and Adverse Effects
In recent years, the development of newer monoamine transporter inhibitors has
been aimed at compounds with an improved selectivity toward SERT and/or NET, as
demonstrated by the selective serotonin reuptake inhibitors (SSRIs), the selective
norepinephrine reuptake inhibitors (NRIs), as well as the dual inhibitors of SERT and
NET (SNRIs) (Andersen et al., 2011). These drugs are among the most frequently
4

prescribed for treatment of depression and anxiety disorders (Andersen et al., 2009) and
have far fewer adverse side effects as compared to the TCAs or MAO inhibitors
(Anderson, 2000). Although rare, SSRIs may be accompanied by a potentially lethal
condition known as serotonin syndrome (SS). SS results from excessive serotonergic
activity and is characterized by autonomic instability and neuromuscular abnormalities.
Many drugs have been linked to SS, which typically develops in patients within hours of
initiating treatment, after dosage increase, or overdose (Boyer and Shannon, 2005; SunEdelstein et al., 2008).
A study published by Schlessinger et al. (2011) found that the adverse side effects
generally associated with antidepressants may be, in part, due to the administration of
drugs for the treatment of diseases that are seemingly unrelated to MAT function, such as
diabetes, which additionally act to inhibit NET activity. This finding may point to the
involvement of the MATs, and in particular NET, in the progression of entirely dissimilar
illnesses (Schlessinger et al., 2011).

For example, about 80 –90% of the released

norepinephrine is taken up again by postganglionic adrenergic neurons through the NET.
Therefore, changes in NET function may have serious cardiovascular and metabolic side
effects (Boschmann et al., 2002). Moreover, it is believed that long-term treatment with
antidepressants which inhibit the NET causes down- regulation of -adrenoceptors (Beer
et al., 1987; Vetulani and Nalepa, 2000; Gould et al., 2003).
Norepinephrine‘s effects are mediated by three families of adrenergic receptors: 1,
2, and  (Bylund et al., 1994). The 1-adrenergic family is mostly postsynaptic and
excitatory.

Alpha1-adrenergic receptors are coupled to phospholipase C and

phosphoinositol secondary messengers through Gq proteins and are responsible for the

5

contraction of vascular smooth muscle. Therefore, an imbalance in the 1-adrenergic
receptors can lead to an increase in blood pressure. In the CNS, 1 receptors are found
in both neurons and glial cells and are involved in motor control, learning, memory, and
fear (Tanoue et al., 2003).
The 2-adrenergic family includes the 2A, 2B, and 2C subtypes, which are
located both pre- and post-synaptically (Bylund, et al., 1994).

Alpha2-adrenergic

receptors are coupled through Gi/o proteins to the second messenger adenylate cyclase,
which is involved in regulating concentration of cyclic adenosine monophosphate
(cAMP). Alpha2A receptors are linked to different adverse effects, including analgesia,
hypothermia, sedation, and control of noradrenergic activity (Crassous et al., 2007). The
alpha2B receptors generally mediate vasoconstriction (Starke, 2001).
Regarding the 2C receptors, although their role is not fully understood they are
associated with motor behavior, mood and memory (Starke, 2001). The 2 agonist and
antischizophrenia drug, clonidine, is administered for different conditions such as
hypertension, opioid withdrawal, and ADHD (Raistrick et al., 2005; Posey and
McDougle, 2007).

Clozapine binds to a variety of serotonergic, dopaminergic,

muscarinic, adrenergic, and other receptors that contributes to its high efficacy, yet
simultaneously, leads to serious side effects including agranulocytosis, seizure, weight
gain and as mentioned above, diabetes (Roth et al., 2004; Keiser et al., 2007).
Beta-adrenergic receptors include the 1, 2, and 3 subtypes (Bylund, et al.,
1994), which are coupled via Gs to adenylate cyclase (Ramos and Arnsten, 2007).
Stimulation of 1-adrenergic receptors increases heart rate and cardiac contractility;
stimulation of 2-adrenergic receptors, which are located in smooth muscle, causes
6

vasodilatation and bronchial relaxation. These receptor subtypes are also found in the
brain, but their functions there are not well known (Ramos and Arnsten, 2007).
Medications that block the -adrenergic receptors are commonly used for a wide variety
of conditions including hypertension, ischemic heart disease, migraine, and performance
anxiety (Limmroth and Michel, 2001; Ong, 2007).
Furthermore, the TCA antidepressant, imipramine, is a dual-acting inhibitor of
SERT and NET, while inhibiting cardiac Na+ channels and G protein-coupled receptors,
including those for acetylcholine, norepinephrine and histamine. The lack of selectivity
of TCA drugs is responsible for their serious adverse effects and toxicity (Iversen, 2000).
These examples suggest that it is necessary to seek new NET inhibitors that would act
more selectively on a particular receptor.

1.2.4 Synaptic Transmission of the MATs
Reuptake of a monoamine neurotransmitter by its transporter protein is the primary
mechanism by which the biological effects in the synapse are terminated (J. Zhou, 2004).
Figure 1.1 illustrates a monoaminergic neuron in synaptic transmission.
In the presynaptic terminals of monoaminergic neurons, a vesicular
monoamine transporter (VMAT) carries the cytoplasmic neurotransmitter (either
serotonin, dopamine, or norepinephrine) into synaptic vesicles, where it is stored and
released from nerve terminals into the synapse once the neuron fires (Cooper et al.,
2003). The activity of 5-HT, DA or NE in the synapse is most often terminated by rapid
MAT uptake of the neurotransmitter into presynaptic terminals.

Neurotransmitter

metabolism is a second termination mechanism, achieved through monoamine oxidase
7

(Dostert et al., 1989; Bonisch and Bruss, 2006) or catechol-O-methyl transferase
(COMT) (Huotari et al., 2002).
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Monoaminergic Neuron
Presynaptic Neuron

VMAT

MAT

Synaptic Cleft

Monoamine Receptors
Postsynaptic Neuron

Figure 1.1. A monoaminergic synaptic terminal showing the role of the SLC6 NTTs
in synaptic transmission. In the presynaptic terminals of monoaminergic neurons,
vesicular monoamine transporters (VMATs) sequester either serotonin, dopamine or
norepinephrine (blue spheres) into synaptic vesicles (purple circles). The MATs are
responsible for reuptake of monaminergic neurotransmiters in the synaptic cleft which
terminates their action. After reuptake by the MAT some of the neurotransmitter is
restored in vesicles, after the uptake by the VMAT. Released neurotransmitter activates
receptors located on the postsynaptic neuron membrane.
9

Synaptic monoamine concentrations can be affected by medications that target their
synthesis or degradation. For example, MAO, COMT and MAT inhibitors all act by
increasing synaptic monoamine levels and are used to treat many neuropsychiatric
disorders (Keating and Lyseng-Williamson, 2005).

1.3 Norepinephrine Transporter (NET)
Two major noradrenergic neuronal clusters in the brain, the locus coeruleus and
the lateral tegmental group, provide extensive innervation to the striatum, amygdala,
hypothalamus, thalamus, cerebellum, and neocortex (Moore and Bloom, 1979). The
NET is located in the plasma membrane of the noradrenergic neurons, where it functions
to take up synaptically released norepinephrine (NE) (Pacholczyk et al., 1991).

1.3.1 Norepinephrine Synthesis and Function
Despite the large body of data available for the monoamine SLC6 family, the
NET remains the least explored MAT.

Norepinephrine (NE), also known as

noradrenaline, is a neurotransmitter found in the sympathetic nervous system and
biosynthesized from the amino acid tyrosine, which is sequentially hydroxylated to
generate dihydroxyphenylalanine (Dopa), decarboxylated to produce dopamine, and
finally, hydroxylated to form NE (Axelrod, 1974).

It is involved in a variety of

physiological functions, including mood and sleep regulation, expression of behavior,
alertness and arousal (Young et al., 1998). Norepinephrine also exerts central control
over the endocrine and autonomic nervous systems (Tellioglu and Robertson, 2001),
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which play a fundamental role in the anxiety and stress response (Tsigos and Chrousos,
2002).

1.3.2 NET Inhibitors
NET is an established molecular target for the treatment of conditions such as
attention-deﬁcit/hyperactivity disorder, substance abuse, Alzheimer‘s and Parkinson‘s
diseases (Macdougall and Griffith, 2008). Low levels of NET mRNA and protein have
been found in brains of suicidal patients with major depression (Hahn and Blakely,
2007).
Unlike the relatively nonspecific tricyclic antidepressants, newer-scaffold NET
inhibitors can exert their effects rather selectively.

For example, the ADHD drug

atomoxetine (Strattera®) is a norepinephrine reuptake inhibitor (NRI) that is highly
specific for NET (Schlessinger, et al., 2011). Certain high affinity NET ligands also
inhibit the SERT, which enhances antidepressant properties e.g., SNRIs such as
venlafaxine (Effexor®) and duloxetine (Cymbalta®) (Hahn and Blakely, 2007).

1.4 Leucine Transporter (LeuT)
Attempts to determine the tertiary structures of SLC6 transporters were
unsuccessful for the first 25 years following the cloning of cDNAs encoding these
proteins. This was due to the inability to obtain sufficiently pure and stable transporter
protein in quantities essential for protein crystallization (Tate and Blakely, 1994; Tate,
2001; Tate et al., 2003; Rasmussen and Gether, 2005) as well as the additional difficulty
of crystallizing membrane (nonsoluble) proteins. Before the determination of the first
11

high-resolution X-ray crystal structure of a bacterial SLC6 homolog, structural
knowledge of SLC6 MATs was based on indirect observations derived from extensive
biochemical and mutagenesis studies that provided valuable information into transporter
topology and secondary structure, but limited data on the tertiary structure. This was
transformed in 2005 when Yamashita et al. (2005) revealed a high-resolution X-ray
structure of a prokaryotic homolog to the SLC6 transporters, the leucine transporter
LeuT, from the thermophilic bacterium Aquifex aeolicus (Kristensen, et al., 2011).

1.4.1 LeuT Structure
The structure confirmed certain predictions made for the SLC6 transporter
architecture by demonstrating 12 transmembrane (TM) regions connected by short intraand extracellular loops with intracellular N and C termini (Kristensen, et al., 2011), along
with a high-affinity substrate binding site (denoted the S1 site) centrally located in the
core of the transporter protein. Unexpected were the two bundles of TMs 1 – 5 and 6 –
10, the centrally-hinged TM 1 and TM 6 -helices, and a second substrate binding site
(S2) in the extracellular vestibule (Z. Zhou et al., 2009; Piscitelli et al., 2010).
The LeuT provided the first credible template to better characterize MAT drug
binding regions and has shown to be an excellent structural template for construction of
MAT homology models, aiding in the discovery of ligand binding pockets and general
binding requirements of substrates, ions, and inhibitors (Andersen, et al., 2011).
Although there is modest homology between the MATs and LeuT, residues that comprise
their ligand binding sites are not identical. Therefore, new approaches still need to be
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developed in order to gain more insight into the structure and function of the monoamine
transporters, specifically the NET.

1.5 Drug Design

1.5.1 The Art of Drug Design
Before the era of computational chemistry, new drugs were discovered through
experimental (wet lab) trial and error (Lee et al., 2011). With scientific progress, active
compounds were isolated and purified, from which researchers were able to infer their
chemical structures (Sneader, 2005). Further advancements in the fields of molecular
biology and biochemistry defined the notion of a so-called ―ligand-receptor relationships‖
(Drews, 2000). Soon after, molecular modeling programs were created that were capable
of discovering novel ligands relevant for a particular binding site. With this, the art of
drug design emerged.
The objective in drug design is to identify a protein target that has been implicated
in a certain disease, and discover compounds that activate or inhibit that target (Moon
and Howe, 1991; Drews, 2000). The discovered compounds should show high target
affinity, triggering a series reactions that lead to an improvement in the condition (Sleno
and Emili, 2008). Progress in the field of drug design allowed the binding mode of a
protein-ligand complex to be better understood using in vitro and in silico approaches.
The in vitro method, known as high-throughput virtual screening (HTVS), is an effective
computational approach for evaluating large chemical structure libraries with the goal of
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discovering hit compounds that interact with a specific biological target (Schneider et al.,
2008).

Combinatorial chemistry and HTVS represent an important step in drug

discovery, reducing costs, increasing time efficiency, and a new weapon in identifying
potentially high affinity novel compounds (Gasteiger et al., 2003; Varnek et al., 2008).

1.5.2 Pharmacophore Modeling: Yesterday and Today
The German–born physician and scientist

Paul Ehrlich introduced the

pharmacophore concept and coined its definition as ―a molecular framework that carries
the essential features responsible for a drug‘s biological activity‖ (Ehrlich, 1909).
Several decades later, the pharmacophore notion was elaborated by Kier, who stated that
a drug must possess ―those atomic features suitable for the requisite drug–receptor
interaction phenomena,‖ and ―… the appropriate spatial disposition of these features
necessary to bring about the required simultaneous or required sequential interaction
events with the receptor‖ (Kier, 1967; Kier, 1973). Kier‘s definition was refined by
Gund, who defined a pharmacophore as ‗‗a set of structural features in a molecule that is
recognized at a receptor site and is responsible for that molecule‘s biological activity‖
(Gund, 1977). The official IUPAC definition of a pharmacophore is ―the ensemble of
steric and electronic features that is necessary to ensure the optimal supramolecular
interactions with a specific biological target structure and to trigger (or to block) its
biological response.‖ (Wermuth et al., 1998). This is a purely abstract concept that
describes the common steric and electrostatic properties of bioactive compounds with the
target of interest (Seidel et al., 2010).
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From these collective definitions, a

pharmacophore, in short, identifies important features that should comprise an active
ligand (Lee, et al., 2011).
In early pharmacophore-based studies, computational models of pharmacophores
were developed manually with the aid of simple molecular graphics visualization
programs. More sophisticated computer programs have since been designed specifically
for pharmacophore modeling (Markt et al., 2011). Today, 3D pharmacophore modeling
is a conventional in silico technique imparting numerous advantages in drug design.
Pharmacophore models are capable of detecting chemical features that are necessary for
protein-ligand interactions and therefore for biological activity. Further, pharmacophorebased screening makes possible the retrieval of compounds with structurally diverse
scaffolds that might not have been otherwise revealed (Markt et al., 2011).
The goal of pharmacophore-based drug design is to discover novel structural
scaffolds that orient their biologically important groups similarly to the active compounds
comprising the training set, termed scaffold hopping. Its importance is based on the
ability to open new synthetic pathways after many of the analogs of a certain scaffold
have been examined and to discover novel ligands with high binding affinities to a
particular target (Horvath, 2011) and at the same time are more selective.

1.5.3 Ligand-Based versus Structure-Based Pharmacophore Models
There are two approaches in developing pharmacophore models: structure- (SBP)
and ligand-based (LBP) (Wermuth, 1993; Guner, 2000). The structure-based method
reveals chemical features based on the association between a ligand and its binding site.
This technique requires obtaining structural information about the macromolecule and the
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active conformation of the binding ligand. As such, there are three benefits of SBPs over
LBPs:
(1) SBPs can identify novel scaffolds with less bias towards existing ligand
chemotypes.
(2) SBPs can be used as suitable tools for structure-based ligand optimization.
(3) SBPs lead to better understanding of ligand binding sites within the
macromolecular structure (Sanders et al., 2012b).
Despite these advantages of SBPs, their use is limited to cases in which the target
structure information is available (Horvath, 2011). A frequently encountered problem for
SBP drug design is that too many pharmacophore features can be identified for a specific
binding site in a macromolecular target. However, a pharmacophore model comprised of
too many pharmacophore features (i.e., more than seven) may not be appropriate for
applications such as virtual screening (Yang, 2010). Therefore, it is important to select a
limited number of pharmacophore features (typically three to seven) to construct a
pharmacophore query (Yang, 2010).
If there is no structural information of the target protein available, pharmacophore
models can be derived in a ligand-based way. This approach uses common chemical
features within set of ligands (known as a training set) that show desired biological
activity at the target. It is believed that a ligand-based method delivers good results if
enough ligand information is available, and if the training set compounds are known to
bind to the protein at a specific site (Evers et al., 2005).
Although in LBP generation procedures there is always uncertainty about the
binding modes of a ligand-protein structure, there have been a number of studies
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comparing the quality of hit compounds using a ligand-based approach versus a structurebased approach. In a comparative study of LBPs and SBPs for novel histone deacetylase
8 inhibitors, the LBP model contained four features and retrieved 117 compounds, of
which 87 were active.

The SBP model contained six features and retrieved 74

compounds, of which 63 were active (Thangapandian et al., 2010).

These data

demonstrate that the ligand-based method can be just as useful as the structure-based
method in producing a high hit rate. LBP modeling has become a key computational
strategy for facilitating drug discovery when a macromolecular target structure is not
obtainable (Yang, 2010). Although structure-based drug design is an attractive approach,
a ligand-based method is useful for finding pharmacophoric features that could facilitate
the discovery of novel high-affinity ligands (Dash et al., 2012).

1.5.4 Guide to Generating a Pharmacophore Model

1.5.4.1 Generation of the Training Set (TS)
The first step in developing a ligand-based pharmacophore model is to collect an
active compound set (or training set), generally from literature searches (Lee, et al.,
2011). Ligand-based pharmacophores can be created from one or multiple active ligands
(Leach et al., 2010). When choosing a training set, all selected molecules must exert
their biological effect through the same mechanism (van Drie, 2003). Furthermore, the
type of training set molecule, the size of the dataset and its chemical diversity have a
great effect on the created pharmacophore model (Yang, 2010). A training set including
active molecules with the same chemical scaffold can cause the so-called analog bias. In
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this case, the pharmacophore model will ignore all compounds different from the single
scaffold from which it has been derived. This bias contributes to inaccurate predictions
and leads to an increase in the number of false positives and false negatives, and certainly
less true positives. Therefore, an important aspect to consider when choosing training set
compounds is structural diversity (Markt et al., 2011).

1.5.4.2 Alignment of TS compounds
The next step is to build the pharmacophore model from the common features
found among the training set ligands (Yang, 2010). To find common features, the ligands
comprising the active set are aligned and conformations of each compound are generated.
Once all training set compounds have been aligned, pharmacophore models are created
through a pharmacophore elucidation algorithm. This algorithm works by compiling
common features among all active set compounds (Molecular Operating Environment
2010). More than one model is commonly produced from this procedure, and selecting
the best one is a significant task (Guner, 2002).

1.5.4.3 Selecting the Optimal Pharmacophore Features
The first and most crucial step in pharmacophore modeling is selecting the right
chemical feature types for the development of a high quality pharmacophore model
(Wolber et al., 2008). Classically, pharmacophore feature designation has several rules:
alkyl chains and halide groups are labeled as hydrophobes; aromatic rings may either be
placed into a specific ―aromatic‖ category or classified with the hydrophobes (Horvath,
2011). It is also desirable to choose specific pharmacophore features such as ―Hydrogen
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Bond Donor‖ or ―Hydrogen Bond Acceptor‖ to denote a particular chemical group rather
than selecting a nonspecific pharmacophore feature such as ―Hydrogen Bond Donor or
Hydrogen Bond Acceptor or Hydrophobe‖.

1.5.4.4 Validation
Once the best model is chosen it should undergo a validation process using
ligands that are not included in the training set. It is ideal for a validation database to
contain structurally diverse active and inactive compounds (Rohrer and Baumann, 2009).
A good model should maximally select the active and ignore the inactive compounds. If a
pharmacophore model cannot pass this validation, it should be discarded and the
modeling process refined (Lee, et al., 2011). Only after a model has satisfactorily passed
the validation step can the virtual screen be initiated.

1.5.4.5 Virtual Screening (VS)
Pharmacophore-based screening is a virtual screening (VS) method that can
automatically evaluate millions of compounds with the use of a computer program
(Walters et al., 1998). Virtual screening works by matching each molecule in the virtual
database to the pharmacophore model. A search algorithm aligns the molecule to the
query using rigid-body superposition. Each match (known as a hit) is based on the
mapping between the database molecule annotation points and the features of the model.
For an efficient virtual screen, MOE discards conformers that do not match feature types
or appropriate inter-feature distances of the pharmacophore model (Molecular Operating
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Environment 2008). The search then outputs all matches that satisfy the constraints of
the query (Seidel et al., 2010).
The first part of the VS process involves assessing how ―druglike‖ are the virtual
database molecules.

Compounds are usually considered drug-like if they fulfill the

Lipinski‘s Rule of Five requirements (Bielska et al., 2011). To obtain more of these
―druglike‖ molecules in a database, reactive, toxic or otherwise unsuitable compounds
should be removed using specific filters. Examples of some common reactive functional
groups include alkyl halide peroxide and carbazide. Unsuitable molecules may include
crown ethers, disulfides, aliphatic chains of seven or more methylene groups, quinones,
polyenes and cycloheximidine derivatives (Vyas et al., 2008).

1.6 Ranking of Hit Compounds
From the virtual screen, an algorithm calculates a score to describe the quality of
the match between the pharmacophore model and each molecule of the VS hit list
(Langer et al., 2006). In MOE this score is a root mean square deviation (RMSD)
calculation, based on the superposition of the pharmacophore features and the output hit.
A low RMSD score corresponds to a good alignment between model and conformer
features (Molecular Operating Environment 2008). Alternatively, another approach to
score compounds is based on their overlay to the alignment of the original training set
compounds, known as an ―S‖ score.

The overall step-by-step scheme of a

pharmacophore-based virtual screen is represented in Figure 1.2.
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Figure 1.2. Schematic illustration of a ligand-based pharmacophore screening. The
first step involved a literature search for active NET inhibitors.

From these NET

inhibitors, a group of compounds were selected to comprise the Training Set (TS). The
TS compounds were aligned in Molecular Operating Environemnt (MOE). A virtual
database was then created, which was used for screening by the created pharmacophore
model. Based on the alignment of TS compounds, MOE output pharmacophore features
which were validated and refined. The refined model was then used to virtually screen
the database of compounds. The hit compounds that MOE retrieved were sorted and
chosen for pharmacological assessment.
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1.7 Software Packages and Pharmacophore Features
An important point to note when creating the pharmacophore query and assessing
hit compounds is that the output may be a function of the software package. Software
packages besides MOE used for pharmacophore-based screening include Phase, Catalyst
and LigandScout. Each software uses its own classification to define particular features
(Wolber et al., 2008). Figure 1.3 (as adapted from Wolber et al., 2008) illustrates two
molecules containing several hydrophobic centers uniquely defined by each software
program.
Taking the pentane molecule in the first example, both Catalyst and MOE
assigned three similar hydrophobic centers; Phase and LigandScout generated two
hydrophobic centers for the same compound, also in a similar space with respect to one
another. In the pentylbenzene molecule, LigandScout and Catalyst both assigned three
hydrophobic centers in the same spatial orientation. Conversely, MOE designated two
points, but not in the benzene ring. Phase created only one hydrophobic point, located
between the third and fourth carbons of the pentyl moiety. From these two molecules in
Figure 1.3, it can be seen that different software packages uniquely designate
pharmacophore centers. While there are similarities among these four programs in terms
of pharmacophore feature designation, each software distinctly situates the number and
orientation of these features, ultimately leading to the retrieval of different hits
compounds.
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Phase

Catalyst

LigandScout

MOE

Figure 1.3 Hydrophobic features defined as a function of the software packages.
Green spheres represent a hydrophobic pharmacophore feature. The top row illustrates a
pentane molecule; the bottom row, a pentylbenzene. From this figure it can be seen that
each software program has a unique way of designating the location and number of
hydrophobic centers in each molecule.
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1.8 Inactive Hit Compounds
After analyzing different aspects that could affect the type of hit retrieved in a
pharmacophore-based screening, some matches still do not show activity at a particular
target, as was seen in this investigation. There are several reasons for the inactivity of a
VS hit compound. According to Martin:

1. A compound can contain groups that sterically prevent interactions despite its
ability to satisfy the pharmacophore query.
2. A compound can contain groups that are unfavorable to activity.
3. A compound may be less soluble that its bioactive conformation
(Martin, 2000).

1.9 Rational Drug Design
In this study, rational drug design will be used to discover novel NET inhibitors.
It is rational because computational models will guide pharmacological analysis.

A

pharmacophore model based on NET inhibitors will be created in silico, using the MOE
software package, comprising a series of structurally diverse compounds chosen from the
literature.

The created model will then be used to virtually screen an extensive

compound database. ―Hit‖ compounds, which are structures predicted to have high
affinity at the NET, will be evaluated by in vitro pharmacology. Unlike conventional
HTS, which involves pharmacologically evaluating a vast number of compounds until a
hit is found, the prospective approach is much less expensive, less time-consuming, and
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certainly more rational. Using the proposed pharmacophore model, novel, high affinity
NET ligands could be discovered for the treatment of disorders mentioned above,
including anxiety, depression, drug abuse, and attention deficit hyperactivity disorder.

1.10 Conclusion
Researchers from a variety of disciplines ranging from biological psychology to
biophysics investigate the mechanisms involved in depression, anxiety and addiction.
This study seeks to understand the basis of such conditions by exploring one of the most
targeted proteins associated with these illnesses – the monoamine transporters (MATs).
The discovery of novel ligands that vary both in their selectivity profiles and potency at
the three MAT proteins may be of value in unraveling the relevant pharmacological
mechanisms, aiding in the discovery of new therapies with fewer side effects (J. Zhou,
2004). Specifically, the approach in this study involves the use of computer-generated
models to better understand molecular structure and function of the MATs, with a
particular focus on the norepinephrine transporter (NET) as well as search for novel
inhibitors of the MATs.

Relying on these models, in vitro experiments could be

performed to test the affinities of the potential MAT inhibitors. The continued interest in
the development of new NET inhibitors combined with the lack of available MAT
crystallographic structures prompted us to explore the possibility of developing ligandbased pharmacophore model(s) for NET inhibitors. It is the hope to be able to identify a
novel class of potent NET inhibitors.
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Chapter 2. Materials and Methods

2.1 Materials

2.1.1 Facilities
Laboratories – Mellon Hall of Science, Rooms 214, 456, 414.

2.1.2 Cell Lines
HEK-293 human embryonic kidney cells, stably transfected with wild type NET
(University of Pittsburgh, Pittsburgh, PA)

HEK-293 cells, stably transfected with wild type SERT
(University of Pittsburgh, Pittsburgh, PA)

N2A (murine neuroblastoma) cells, stably transfected with wild type DAT
(University of Michigan, Ann Arbor, MI)

2.1.3 Chemicals and Drugs
[3H]-Nisoxetine
Perkin Elmer, Foster City, CA
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[3H]-Paroxetine
Perkin Elmer, Foster City, CA

[3H]-WIN 35,428
Perkin Elmer, Foster City, CA

Dimethylsulfoxide (DMSO)
Sigma Chemical Co., St. Louis, MO

Dulbecco's Modified Eagle Medium (DMEM)
Hyclone, Logan, UT

HBSS/modified
Hyclone, Logan, UT

Opti-MEM 1
Invitrogen, Carlsbad, CA

ScintiSafe scintillation fluid
Fisher Scientific, Pittsburgh, PA

Trizma base
Fisher Scientific, Pittsburgh, PA
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Trypsin-EDTA (1x)
Invitrogen, Carlsbad, CA

2.1.4 VS-identified Compounds
AC-1
2-(3-fluorobenzoyl)-1-(4-methoxyphenyl)octahydro-4a(2H)-isoquinolinol
Aurora Fine Chemicals, San Diego, CA

AC-2
2-[(4-ethylphenyl)-(2-methoxy-5-methylphenyl)sulfonylamino]acetamide
Aurora Fine Chemicals, San Diego, CA

AC-3
5-(furan-2-yl)-3,3-dimethyl-2,4,5,6-tetrahydrobenzo[b]phenanthridin-1-one
Aurora Fine Chemicals, San Diego, CA

AC-4
3-[1-(2-methoxybenzyl)-1H-benzimidazol-2-yl]-1-propanol
Aurora Fine Chemicals, San Diego, CA

AC-5
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[4-hydroxy-6-(4-methylphenyl)-2-thioxo-4-(trifluoromethyl)hexahydro-5pyrimidinyl](phenyl)methanone
Aurora Fine Chemicals, San Diego, CA

AC-6
2-(3-hydroxypropyl)-1-(3-methoxyphenyl)-1,2-dihydrochromeno[2,3-c]pyrrole-3,9-dione
Aurora Fine Chemicals, San Diego, CA

2.1.5 Other Materials
Cell culture flasks, 75 cm2
Corning Inc., NY

Centrifuge tubes, 15 ml
Corning Inc., NY

Falcon tubes, 14 ml
Fisher Scientific, Pittsburgh, PA

Falcon tubes, 50 ml
Fisher Scientific, Pittsburgh, PA

Eppendorf microcentrifuge tubes, 1.5 ml
Fisher Scientific, Pittsburgh, PA
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Pipette tips, disposable Redi-Tips (1,10, 200, 1000 l)
Fisher Scientific, Pittsburgh, PA

Scintillation vials
Fisher Scientific, Pittsburgh, PA

2.1.6 Equipment
Analytical balance
Mettler Toledo Inc., OH

Cell culture incubator
Forma Scientific, MA

Centrifuge, Model 228
Fisher Scientific, Pittsburgh, PA

Centrifuge, Model 5415 C
Eppendorf Scientific Inc., NY

Inverted microscope
Olympus, PA
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Lab freezers and refrigerators
Forma Scientific, MA

Liquid nitrogen tank

Millipore Milli-Q and Elix water purification system
Millipore Corporation, MA

pH meter AB15
Fisher Scientific, Pittsburgh, PA

Water bath, 180 series
Precision Scientific, Winchester, VA

Weighing scale
Denver Instruments Co., CO

2.1.7 Computer Software
Molecular Operating Environment (MOE) software, Version 2008.09
Montreal, Canada

Microsoft Office Word and Excel 2008
Microsoft Corporation
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2.2 Methods

2.2.1 Computational Methods
Molecular modeling studies were performed using a dual-core 3.06 GHz iMac and
2.66 GHz quad-core Intel Xeon macpro computer.

Construction and evaluation of

pharmacophore models were performed using MOE 2008.09.

2.2.2 Selecting and Building Active Set Structures
Active NET inhibitors to comprise the training (or active) set were chosen from
literature PubChem and SciFinder searches. The 2D structures of compounds included in
the training set were built using the ―molecule builder‖ function of MOE.

2.2.3 Alignment of Molecules
FlexAlign, an alignment method in MOE that explores the conformational space of
a molecular set based on common chemical features, was used to generate conformers
and align the training set compounds (Esposito et al., 2004).

For each active set

molecule, bonds were randomly rotated and chiral centers inverted, followed by energy
minimization that created ―new‖ molecular conformations.

Once minimized, the

molecules were held rigid and aligned using a similarity function based on the atomic
coordinates. The following equation was used in the alignment process:

Similarity Function = -kt . logF + U,
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where –kT is approx 0.6 kcal/mol, F is the similarity measure derived from the atomic
coordinates, and U is the average potential energy of the system (Esposito et al., 2004).
The FlexAlign alignment search was terminated once the number of consecutive
failed attempts to generate a new molecular configuration based on the initial parameters
was reached (Esposito et al., 2004).

2.2.4 Generation of the Pharmacophore Model
Once training set molecules were aligned, a query of points, which is a compilation
of features, group constraints, and volumes common among all active set compounds,
was generated.

The role of the query is to select a subset from common ligand

conformations such that all restrictions of the query are satisfied (Molecular Operating
Environment 2010). A general diagram illustrating the creation of the pharmacophore
query is shown in Figure 1.
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Figure 2.1. Generation of the pharmacophore query from a molecular alignment.
Small molecules to comprise the training set were chosen from the literature and built in
MOE. The MOE FlexAlign feature was used to create conformations and align training
set compounds. Based on the alignment of the training set compounds, MOE found
common features among all molecules: a donor group (purple sphere), a hydrophobic
group (green sphere) and two aromatic groups (orange spheres). Common features were
represented by colored spheres. Together, all features comprised the pharmacophore
query.

34

The ―pharmacophore query editor‖ was used to create and revise a query consisting
of a set of constraints of ligand annotations. Pharmacophoric structural features were
represented by points in space that reflected the presence or absence of biologically
important atomic features at those locations, known as ligand annotations (Molecular
Operating Environment 2010). The set of pharmacophore features among all active set
compounds created the pharmacophore query (or pharmacophore model).

2.2.5 Validating and Refining the Pharmacophore Query
After the pharmacophore query was generated, it was validated in order to
determine whether it could retrieve active and ignore inactive compounds from a test set
database. All features were amended in a way to maximally retrieve active compounds
at the NET while ignoring inactive compounds. A diagram representing the validation
and refinement scheme is illustrated in Figure 2.
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Figure 2.2.

Pharmacophore query refinement and validation.

A basic query

consisting of features determined by MOE was created based on the alignment of the
training set compounds. A test set database comprising active and inactive compounds
was searched to determine how the query should be refined in order to maximally retrieve
active and minimally retrieve inactive compounds.

The features in the query were

refined accordingly until a satisfactory retrieval ratio of active:inactive compounds was
reached, thus generating the validated and refined pharmacophore query.
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2.2.6 Searching a Conformation Database
The ―pharmacophore search‖ feature of MOE was used to screen the extensive,
virtual ZINC conformational database for compounds that satisfy the pharmacophore
query features. Each ligand conformation from the ZINC database that complies with all
restrictions of the pharmacophore query, known as a hit (or match; Figure 2.3), was
stored in an output hit database. In general, atomic centers within each hit must be
within the radius of the pharmacophore feature to be considered a match (Molecular
Operating Environment 2010).
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Figure 2.3. Pharmacophore searching in MOE. The pharmacophore query, illustrated
with different colored spheres known as pharmacophore features, was used to search the
ZINC database. Compounds that satisfied all features of the query were returned as hit
compounds.
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2.2.7 Sorting the Hit Database
A Gaussian-based scoring algorithm, informally called an ―S‖ score, was used to
rank the compounds in the hit database based on how well hits align to the original
alignment of the four training set compounds. When the four active set molecules were
aligned, the score consisted of a sum of terms that were based on intermolecular atom
pairs. Each intermolecular atom pair with similar properties was calculated using the
Gaussian scoring term:
w exp(-Rr2),
in which r is the distance between the two atoms, R is a parameter controlling the range
of the interaction, and w is the weight of this term (Chan and Labute, 2010).
A scoring function S was constructed based on the sum of Gaussian terms:

In the above formula, Tk represents the overlap of a particular pair of atom types or
features (Ak, Bk); wk is the weight of the term; i and j are atoms/features from the two
molecules; rij is the distance between the intermolecular atom/feature pair; and  is a
parameter controlling the range of this type of interaction (Chan et al., 2010). For details
on the ―T‖ terms, please refer to Chan and colleagues (2010).
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2.3 Experimental Methods

2.3.1 hNET and hSERT Membrane Preparation
Membranes were prepared from stably transfected HEK293-hNET and HEK293hSERT cells grown at 37oC in a 5% CO2 environment on 150 х 25 mm plates. At 95%
confluence (3 days of growth), cells were washed twice with 10 mL cold phosphatebuffered saline (DPBS). An additional 10 mL of DPBS was added to the plates, and cells
were detached by scraping and transferred to cold centrifuge tubes (15 mL). Cells were
centrifuged for 10 min at low speed (700 x g). The supernatant was removed and the cell
pellet was resuspended in 500 L cold TE buffer (50 mM Tris, 1 mM EDTA, pH 7.5).
Following centrifugation for 30 min at 100,000 x g at 4 oC, the supernatant was discarded
and the pellet was frozen and stored at -20oC for later use.

2.3.2 hNET and hSERT One-Point Binding Assays
Membrane one-point binding assays were performed for hNET and hSERT using
stable hNET-HEK293 and hSERT-HEK293 cell lines, respectively. hNET and hSERT
membrane pellets were resuspended in ice-cold binding buffer (50 mM Tris, pH 7.5, 100
mM NaCl). The membranes were sonicated until the pellet dissolved. Each compound
identified from the virtual screen was dissolved in 100% DMSO to a concentration of 10
mM. Initial one-point competition binding assays were conducted using 10 M final
concentration of VS hit compounds and 10 nM of radiolabeled [ 3H]-nisoxetine and [3H]paroxetine for NET and SERT, respectively. Reactions were carried out in 12 х 75 mm
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borosilicate glass tubes. Each tube contained 240 L membrane, 30 L radioligand (10
nM [3H]-nisoxetine or [3H]-paroxetine), and 30 L cold competitor VS compound (to
final concentration of 10 M). To measure non-specific binding, an additional tube
contained similar amounts of membrane fraction, radioligand, and 10 μM non–specific
competitor (desipramine or paroxetine for hNET or hSERT, respectively). Tubes were
gently shaken at room temperature for 1 hr. GF/B filters (Schleicher and Schuell, Keene,
NH) were presoaked in 0.5% polyethylenimine solution (v/v). Solutions were rapidly
filtered through GF/B filters using a Brandel harvester. Filters were washed twice with 5
mL cold 50 mM Tris buffer. Each filter was transferred to scintillation vials containing 5
ml of ScintSafe and radioactivity was counted using a liquid scintillation counter.
Screening results were analyzed using Microsoft Office Excel software.

Data were

compared using Student‘s t-test; values less than 0.05 were considered to be statistically
significant.

2.3.3 hDAT Whole Cell Binding Assays
Whole-cell one-point binding assays were performed for hDAT using stable hDATN2A cell lines, grown at 37oC in a 5% CO2 environment. Cell monolayers were grown in
24-well plates to >90% confluence. Cells were washed twice with 1 mL of KRH buffer
(25 mM HEPES, pH 7.3, 125 mM NaCl, 4.8 mM KCl, 1.3 mM CaCl2, 1.2 mM MgSO4,
1.2 mM KH2PO4, 5.6 mM glucose) supplemented with 50 mM ascorbic acid (KRH/AA).
Each compound identified from the virtual screen was dissolved in 100% DMSO to a
concentration of 10 mM. Cells were incubated for 15 min with 10 nM [ 3H]-WIN 35,428
(total volume of 500 uL) along with 10 M VS hit compound or 10 M mazindol.
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Following incubation, cells were washed twice with 1 mL KRH/AA buffer, then treated
with 1 mL 1% SDS with gentle shaking at room temperature for 1 hr. Cell lysates were
transferred into vials. Radioactivity was determined in a liquid scintillation counter.
Screening results were analyzed using Microsoft Office Excel software.

Data were

compared using Student‘s t-test and values less than 0.05 were considered to be
statistically significant.
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Chapter 3. Computational Studies

3.1 Pharmacophore Model Generation and Virtual Screening

3.1.1 Introduction
A pharmacophore model demonstrates the interaction between the active site of a
target protein and a ligand. Yet, this is not entirely a new concept. The expression
―pharmacophore‖ was first coined by Paul Ehrlich and defined as: ―a molecular
framework that carries the essential features responsible for a drug‘s biological activity‖
(Ehrlich, 1909). Pharmacophore features include important functional groups involved in
intermolecular interactions; the combination of these features in three-dimensional space
represents the necessary components for a ligand to be active against a certain target
(Pandit et al., 2006). A pharmacophore model demonstrates the interaction between the
active site of a target protein and a ligand. In this study, because the 3-D structure of the
NET (or any of the monoamine transporters) is not available, high-affinity NET
inhibitors were used to generate the pharmacophore model in an approach known as
―ligand-based drug design‖.
Several steps were involved in generating the pharmacophore model. The first was
to select known receptor ligands to comprise the ―training set‖. The 2-D structures of
each ligand were built in MOE. The next step involved aligning common features found
among all of the compounds in the training set. Upon completion of this alignment,
pharmacophore models were generated using the MOE algorithm, and the more favorable
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set of pharmacophore features in each model were selected. The model deemed best was
subjected to a validation and refinement process using ligands not present in the training
set; models that did not pass this validation step were rejected.

The constructed

pharmacophore model was then used to virtually screen the extensive ZINC database.
―Hits‖ from the screening were ranked using a MOE scoring function, and the highestranked compounds were analyzed in vitro at the NET, DAT and SERT.

3.1.2 Generation of the Training Set
The training set is comprised of structurally diverse compounds of known
biological activity.

3.1.2.1 Searching for Relevant Compounds: Literature Review
A thorough literature search was performed to seek out compounds with
experimentally determined Ki values at the NET. Table 3.1 shows these compounds
from a variety of studies. Considered investigations involved the use of either membrane
fractions or whole cells of HEK-293 or MDCK cell lines, both stably transfected with
NET as well as cells from male rat Sprague-Dawley cerebral cortex. Only literature
sources using tritiated nisoxetine as the radioligand in each experiment at the NET were
considered and shown in Table 3.1.
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Table 3.1.

Binding affinities of NET inhibitors from radioligand competition

binding assays. In each case [3H]-nisoxetine was used as the radioligand. Whole cells
or membrane fractions were prepared from stably transfected HEK293-hNET, MDCKhNET or cerebral cortex sections from male Sprague-Dawley rat cells.

Compound

Ki for hNET (nM)a

Cell type

Amitriptyline

19±1

HEK-2931

13.3±1.54

HEK-2934

16

HEK-2935

2

HEK-2936

5

MDCK2

3.5±0.3

HEK-2937

>10,000

MDCK2

185,000±17,000

HEK-29310

Amoxapine

Atomoxetine

Bupropion

45

7865±304

HEK-2931

4870±149

HEK-2934

4070

HEK-2935

38

HEK-2935

79

HEK-2936

144±21

HEK-2937

53.7

MDCK8

20,000±2500

HEK-29310

1990

Cerebral cortex (male
Sprague-Dawley rats)13

Desipramine

0.63±0.03
3.8
1.58
0.83
2.3±0.2
0.6

HEK-2931
MDCK2
HEK-2936
HEK-2935
HEK-2937
MDCK9

Duloxetine

7.5± 0.3

MDCK3

1.17±0.11

HEK-2934

7.3±0.5

HEK-2937

6.3

HEK-2936

Citalopram

Clomipramine

Cocaine

46

Fluoxetine

Imipramine

Maprotiline

Mazindol

MCN5652

777±37

HEK-2931

1022

MDCK2

20±0.54

HEK-2931

98

MDCK2

98±22

HEK-29310

11.1

HEK-2935

12

MDCK9

0.46±0.004

HEK-2931

3.42±0.67

HEK-29310

15.8

HEK-2936

47

Methylphenidate

339

MDCK2

Milnacipran

22±2.58

HEK-2934

50.1

HEK-2936

6

MDCK9

6±0.5

HEK-29310

29

MDCK2

71±6

HEK-29310

1.8±0.07

HEK-2931

1.49±0.17

HEK-2934

4.35

HEK-2935

17±0.5

HEK-29310

Nisoxetine

Nomifensine

Nortriptyline

48

Oxaprotiline

4.9

HEK-2935

Paroxetine

85±5

HEK-2931

40

HEK-2935

63

HEK-2936

Protriptyline

1.41

HEK-2935

Reboxetine

0.3

MDCK9

15.8

MDCK8

11

MDCK3

21.8±0.6

Cerebral cortex (male
Sprague-Dawley rats)13

RTI-112

49

Sertraline

817±80

HEK-2931

Venlafaxine

2269±84

HEK-2931

2480±43

MDCK3

1920±158

HEK-2934

3346

HEK-2936

6310

MDCK8

Zimelidine

9400±100*

HEK-2935

3

0.76 ± 0.06

HEK-29311

14

9

MDCK9

50

S3305

1510

MDCK8

8d

0.43±0.02

Cerebral cortex (male
Sprague-Dawley rats)12

Data are expressed as geometric means ± standard deviation of at least three separate
experiments performed in triplicate.
a

Radioligand competitive binding using [3H]nisoxetine in cells transfected with a human

norepinephrine transporter cDNA plasmid.
*Value shown as KD
1: Owens et al., 1997

7: Wagstaff et al., 2007

2: Bymaster et al., 2002

8: Millan et al., 2001

3: Bymaster et al., 2001

9: Heffernan et al., 2009

4: Vaishnavi et al., 2004

10: Eshleman et al., 1999

5: Tatsumi et al., 1997

11: Zeng et al., 2008

6: Tsuruda et al., 2010

12: Carroll et al., 2005
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3.1.2.2 Examining compound combinations
All compounds used in the training set were high-affinity NET inhibitors.

A

variety of compound combinations were explored before the final set was selected. Table
3.2 depicts the diverse groupings of training set compounds. The first training set attempt
included five chemically unique compounds. The second set comprised compounds with
the highest affinity at the NET. The third set consisted of two TCA and two non-TCA
high-affinity NET ligands. The tactic used for choosing the training set compounds is
based on the ―one group—one type‖ policy (Horvath, 2011), meaning that a
pharmacophore feature should contain one chemical feature type such as ―Donor‖ or
―Hydrophobic‖, rather than a ―one group—many types‖ approach such as a ―Donor or
Hydrophobic‖ group (elaborated in more detail in section 2.1.3 and in section 5.4.2 of
discussion.
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Table 3.2. Compound combinations explored prior to choosing final training set.
All compounds used in the training set are high-affinity NET inhibitors.

The first

training set attempt included five chemically distinct compounds (a). The second set
consisted of compounds with the highest affinity at the NET (b). The third set comprised
two TCA and two non-TCA high-affinity NET ligands (c).

(a) Training Set 1
Chemically distinct structures
Compound

Mazindol

Milnacipran

Paroxetine

RTI-112

Reboxetine

Ki (nM)

3.42

50

63

21.8

0.2

(b) Training Set 2
High-affinity NET ligands
Compound

Maprotiline

Nisoxetine

Protriptyline

Reboxetine

Ki (nM)

11

50

1.4

0.2
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(c) Training Set 3
Two TCA/two non-TCA compounds
Compound

Atomoxetine

Desipramine

Mazindol

Nortriptyline

Ki (nM)

5

1.58

3.42

1.8

Four compounds with nanomolar inhibition potency were chosen as the final
training set: mazindol, milnacipran, reboxetine and ―8d‖ (Table 3.3). The 2D molecular
structures of all ligands used to create the pharmacophore model in the training set were
built and imported into MOE.

These compounds were converted into 3D single

conformer representations using the FlexAlign feature in MOE, which energetically
minimized and aligned all four compounds (Figure 3.1).

Table 3.3. Training set NET ligands used to generate pharmacophore model.

Training Set Compounds
Compound

Mazindol

Milnacipran

8d

Reboxetine

Ki (nM)

3.42

50

0.43

0.2
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3.1.3 Selecting the Optimal Alignment for Creation of the
Pharmacophore Query

Different compound combinations were examined, and the best set was chosen
based on alignment (Figure 3.1) and pharmacophore feature composition. The FlexAlign
feature in MOE was used to align the training set compounds. In selecting the best
alignment, it is ideal to include features which are used alone, such as Acc (hydrogen
bond acceptor) or Don (hydrogen bond donor), or in combination such as Acc|Don
(hydrogen bond acceptor or hydrogen bond donor); it is best to avoid ―or‖ features such
as Aro|Acc|Don|Hyd (Aromatic or Hydrogen Bond Acceptor or Hydrogen Bond Donor or
Hydrophobic).

The Acc|Don feature is much more specific than the ―or‖

Aro|Acc|Don|Hyd feature, which could encompass just about any chemical substituent.
From

alignment

of

the

training

set

compounds

MOE

generated

an

aromatic/hydrophobic feature on the aligned aromatic rings of the four training set
compounds (F2; orange), two projected PiN features on either side of the Aro|Hyd feature
(F1 and F4; red) representing pi bonding from the aromatic ring, an acceptor feature on
the nitrogen or oxygen moieties (F3; cyan), a non-aromatic hydrophobic feature (F5;
green), and a larger aromatic/hydrophobic feature on the aromatic rings of the TS
compounds, located on the opposite side of the first Aro|Hyd feature (F6; orange) (Figure
3.2).
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Figure 3.1.

Optimal alignment of training set compounds mazindol (orange),

milnacipran (cyan), reboxetine (yellow) and 8d (purple).

Nitrogen (blue caps),

oxygen (red caps) and halogen (green caps) atoms are indicated. From this figure it can
be seen how the acceptor/donor groups align.
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Figure 3.2. Preliminary pharmacophore features generated by MOE, based on
training set alignment of mazindol, milnacipran, reboxetine, and 8d.

In the

alignment, MOE grouped common features together. The sky blue sphere represents an
acceptor group located on nitrogen and oxygen moieties (cyan, of 0.91 A radius).
hydrophobic features (green, of 1.41 A radius); groups that are either aromatic or
hydrophobic in character (orange, with radii of 0.89 Angstroms). PiN groups (red, of
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radii 0.70 and 1.07 A) are projected pi-bond hydrogens which usually accompany the
aromatic features.

3.1.4 Validation of the Pharmacophore Model
In order to discern whether the created model could retrieve active compounds and
ignore inactive compounds from a database, validation of the constructed pharmacophore
model was performed. A test set was created by randomly choosing 1000 compounds
from the ZINC database and seeding it with 10 structurally diverse compounds of known
affinities, including five active (high affinity) and five inactive (low affinity) at the NET
(Table 3.4). Conformational analysis for each compound in the validation dataset was
performed, with a maximum number of 100 conformations per molecule. From Table 3.4
it can be seen that both sertraline and venlafaxine have Ki values that are relatively not
large, approximately 0.8 M and 2 M, respectively. In this study, a question of where
to draw the line between active and inactive compounds arose. Generally, compounds
that were approximately 1 M or higher at the NET were deemed inactive.
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Table 3.4. List of high affinity and low affinity compounds at the NET used in
validation studies. The numbers represent Ki values (nM).

Active
Compound

Atomoxetine Duloxetine

Nisoxetine

Paroxetine

3

e

3.51

7.31

62

403

0.34

Compound

Bupropion

SCitalopram

Sertraline

Venlafaxine

Zimelidine

Ki(nM)

185,0002

40703

8175

22695

94003

Ki(nM)

Inactive

1: Wagstaff et al. (HEK-293 cells)
2: Eshleman et al. (HEK-293 cells)
3: Tatsumi et al. (HEK-293 cells)
4: Zeng et al. (HEK-293 cells)
5: Owens et al. (HEK-293 cells)
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The original model selected two inactive compounds (zimelidine and venlafaxine)
and two active compounds (nisoxetine and a reboxetine derivative, ―3‖).

It was

necessary, therefore, to refine the model in such a way so that it would pick out a greater
number of active compounds and ignore inactive compounds, particularly ignoring
extremely low affinity compounds at the NET such as zimelidine or buproprion.

3.1.5 Refining the Pharmacophore Query
In order to maximize the number of active and minimize inactive retrieved
compounds, the pharmacophore features were modified. This was done by trial and
error, systematically making one alteration at a time and screening the test set database to
identify which known compounds were retrieved.
The first modification was to ignore both of the PiN features in order to broaden
searching criteria.

Although this change retrieved all five active compounds, four

inactives (zimelidine, bupropion, citalopram and venlafaxine) were also picked out. This
is a general improvement in the number of active compounds since the screening with
original pharmacophore query retrieved only two active compounds (nisoxetine and ―3‖),
as described in section 2.1.4, above. At the same time, ignoring the PiN features also
increased the number of inactives from two (zimelidine and venlafaxine) to four. From
this screening, it appeared that although the PiN features should remain ignored, as in
their absence all active compounds were retrieved, there needed to be an adjustment that
would narrow searching criteria, such that only the five actives would be selected. Of
particular interest was to exclude in the validation screen zimelidine and bupropion, two
compounds with very low NET affinity.
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The structures of zimelidine and bupropion were overlaid with the pharmacophore
points in order to discern how the features could be modified. The large ―Aro|Hyd‖
feature, located opposite of the smaller ―Aro|Hyd‖, appeared to be in zimeldine‘s
hydrophobic rather than aromatic region. Therefore, both ―Aro|Hyd‖ features were
amended to ―Aro‖ so that zimelidine would not be selected in the validation screening.
Favorably, this change did not retrieve any inactive compounds. Yet, of the active
compounds, only three of the five were selected. The two changes made at this point ignoring the two PiNs and changing the ―Aro|Hyd‖ features to ―Aro‖ - were following
the right path (i.e. retrieval of more actives and ignoring inactives). The next step
involved, again, broadening search criteria in order for more active compounds to be
retrieved.
The acceptor feature is spatially located predominantly on amino groups, as well as
on one of the carboxyl moieties of the training set (Figure 3.2). It was interesting to see
what change would occur if it were to be changed to a donor group.

From this

adjustment, all five actives and three inactive compounds (zimelidine, sertraline and
venlafaxine) were retrieved. Again, the next step involved narrowing search criteria so
that little or no inactive compounds would be selected from the validation screening.
An exterior volume was placed about the training set compounds, with a radius of
1.49 A. This change retrieved two active (atomoxetine and 3) and two inactive
(zimelidine and venlafaxine) compounds.

The exterior volume constraint was

incrementally increased by 0.1 A. At a radius of 2.5 A, three actives and the two
inactives remained; at a radius of 2.7 A, four actives and the two inactives were retrieved.
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Further increasing this radius did not produce any changes. Temporarily, the exterior
volume radius was left at 2.7 A.
The next change was to decrease the radius of the large ―Aro‖ feature from 1.55 A.
It was systematically decreased every 0.1 A until no more changes were observed. At a
radius of 1.0 A, four active compounds and one inactive (sertraline) compound were
obtained. The large hydrophobic feature was also altered in size. It was observed that
retrieved hits depended on the combination of exterior volume radius and the size of this
hydrophobic feature. Decreasing the hydrophobic radius to 0.6 A and exterior volume to
2.2 retrieved all five active compounds and one inactive (sertraline) compound. Since
sertraline is moderately inactive regarding NET affinity (unlike zimilidine or bupropion),
it was deemed an acceptable compromise that the model selected it.

Table 3.5.

Retrieved compounds from the validation database screening after

refining the pharmacophore model. Five active compounds (atomoxetine, duloxetine,
nisoxetine, paroxetine and #3) and one inactive compound (sertraline) were retrieved.

Active
Atomoxetine

Duloxetine

Nisoxetine
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Paroxetine

3

Inactive
Sertraline

3.1.6 Second Refinement of Pharmacophore Query
In order to determine whether the model required further refining and if a
manageable number of hits would be retrieved, a preliminary screen of a portion of the
ZINC database was performed. The filtered ZINC database (as discussed in Section 2.1.7
and shown in

Figure 3.5) was divided into ten separate databases, each containing a

range of 20,000 to 2 million entries.

Database #2 was screened, which contained

approximately 42,000 molecules. After the screen with the initially refined model, about
400 molecules were retrieved. Although this was a manageable hit return, it was only
one small database screened out of ten even larger ones. Therefore, before any further
screening, it was necessary to further revise the pharmacophore features in order to
decrease the hit rate.
To this point, the model had been modified such that it could retrieve five active
compounds and one inactive compound (Table 3.5). Each feature was next made more
stringent by decreasing its radius, given that the selected compounds from the validation
screen should not change. After each change, the validation database was rescreened.
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The radius of each feature was decreased until a change in the number of retrieved
compounds was observed. If the number of selected active or inactive compounds was
altered, the change was reversed. At last, the features were amended to the following
(Figures 3.3 and 3.4):
Aro – 0.78 A (formerly near the PiNs)
Don – 0.8 A
Hyd – 0.55 A
Aro – 1 A
Exterior volume – 2.14 A
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Figure 3.3. The refined pharmacophore model containing four pharmacophore
features, mapped onto the four training set compounds. Features include: an aromatic
feature with radius of 0.78 A (orange, closer to bottom), another aromatic feature with
radius of 1.0 A (orange, larger sphere), a donor feature with radius of 0.8 A (purple),
hydrophobic feature with radius of 0.55 A (green).
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Figure 3.4. Refined pharmacophore model with excluded volume feature, shown in
blue, with a radius of 2.14 Å. The volume is enclosed around the initial four training set
compounds. Blue spheres represent atoms from these compounds.
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All changes to the pharmacophore points gave a maximum number of five active
compounds and a minimum number of one inactive compound, retrieved from the test set
database.

At this point, the model appeared acceptable and virtual screening could be

performed.

3.1.7 Virtual Screening of the ZINC Database
Virtual screening is a fast and economic approach to effectively identify
biologically active compounds, or ―hits‖, from a pool of millions of commercially
available compounds (Waszkowycz, 2002; Shoichet, 2004). The database used in virtual
screening was created in accordance to Manepalli et al. (Manepalli et al., 2011). An 18
million entry ―all-purchasable‖ subset of the ZINC database was downloaded. Using the
MOE software, the compounds were ―washed‖ by removing salts, ions, and disconnected
molecular fragments. To remove non-drug like molecules, The Lipinski‘s Rule of Five
descriptor was applied to the database. Compounds containing reactive groups were
removed with a toxic moiety descriptor filter. From the approximate million remaining
compounds, tautomers and protomers were generated.

Conformational analysis was

performed on these compounds using the ―import conformation‖ module of MOE, with
the MMFF94x force field. Conformations with strain energy 4 kcal/mol or greater were
discarded (Figure 3.5). This final database was screened with the created pharmacophore
model.
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Figure 3.5. Generation of ZINC Database. Sequential filtering steps employed in
screening the ZINC database to attain hit compounds including removing salts, ions, and
molecular fragments; removing non-drug molecules based on the Lipinski‘s Rule of
Fives; removing compounds with reactive groups by applying a toxic moiety filter;
generating tautomers and performing conformational analysis.
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3.1.8 Sorting of Hit Compounds
The virtual screen produced 868 hits. Although this was a manageable hit quantity,
it was necessary to find an approach to rank the hits to determine which compounds
should be chosen and synthesized for further in vitro pharmacological studies. One
scheme was to create clusters based on scaffold similarity. The MOE clustering feature
was used to organize hits by their scaffold constitution into different groups.
Unfortunately, there were so many unique structures that over 200 clusters were
generated, an unacceptably high number.
Another approach was to rank hits by RMSD (root mean square deviation) score,
which is a statistical calculation of how well the pharmacophore centers of the hit
compounds align with the training set pharmacophore centers. The RMSD is a score
given by MOE upon completing the virtual screen. This approach was considered, but a
more relevant method as opposed to RMSD ranking was used known as an overlay (or
―S‖) score. The ―S‖ score is a measure of how hit compounds align to the training set
alignment. A rationale for using an overlay-based method is that it provides the more
appropriate biophysical binding mode of hit compounds, compared to RMSD ranking
(Sanders et al., 2012a).
From visual inspection, it was found that compounds with an overlay score less
than -113 aligned well to the training set alignment.

As a result, 32 compounds

possessed the best (lowest value) ―S‖ score, in a range of about -113 to -116. Out of
these 32 compounds, six unique scaffolds were selected and purchased for in vitro
pharmacological characterization (Table 3.6).
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Table 3.6. Six structurally-distinct hits chosen based on S Score and characterized
in vitro.
Structure

S score
-116

Name of Compound
AC-1
2-(3-fluorobenzoyl)-1-(4methoxyphenyl)octahydro4a(2H)-isoquinolinol

-115

AC-2
2-[(4-ethylphenyl)-(2-methoxy5methylphenyl)sulfonylamino]ace
tamide

-114

AC-3
5-(furan-2-yl)-3,3-dimethyl2,4,5,6tetrahydrobenzo[b]phenanthridin
-1-one

-113

AC-4
3-[1-(2-methoxybenzyl)-1Hbenzimidazol-2-yl]-1-propanol
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-113

AC-5
[4-hydroxy-6-(4-methylphenyl)2-thioxo-4(trifluoromethyl)hexahydro-5pyrimidinyl](phenyl)methanone

-113

AC-6
2-(3-hydroxypropyl)-1-(3methoxyphenyl)-1,2dihydrochromeno[2,3-c]pyrrole3,9-dione

Of the six hits, compound AC-1 seemed to be the most promising due to its S
score and unique chemical composition.

When superimposed on the original four

training set compounds as well as the pharmacophore points, AC-1 appeared to align well
(Figures 3.6 and 3.7).
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Figure 3.6. Superposition of AC-1 (orange) on the original training set alignment.
Compound AC-1 exhibited the best overlay score of -116.
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Figure 3.7.

Superposition of AC-1 on the pharmacophore points.

pharmacophore points represent the refined pharmacophore model.
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The

Chapter 4. Pharmacologic Characterization
4.1 hNET
To examine the VS hits attained from computational studies, the six highly scored
compounds labeled AC-1 to AC-6 were tested for human NET affinity in single point, in
vitro binding assays. The reagents were dissolved in DMSO as described in Materials and
Methods and assessed for their ability to displace 10 nM [3H]-nisoxetine from the NET in
membrane homogenates of hNET HEK293 cells. VS compounds were screened at a
single concentration of 10 μM (1000-fold molar excess relative to the radioligand).
As shown in Figure 4.1 all compounds did not significantly displace the binding
of radiolabeled ligand from the hNET in membrane homogenates (Student‘s t-test,
p>0.05), indicating no hNET affinity. In a parallel control, 10 μM of the established
NET ligand desipramine inhibited the binding of [3H]-nisoxetine by 878% (p<0.05).
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*

Figure 4.1.

VS hit compound one-point screening assay at hNET.

Membrane

homogenates of HEK-293 cells stably transfected with hNET were used in the binding
assay. hNET binding affinities were obtained by displacement of [ 3H]-nisoxetine. All
VS compounds were added at a final concentration of 10 μM. To measure non-specific
binding, 10 μM desipramine was used. * p < 0.05
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4.2 hSERT
The six VS hits attained from computational studies (AC-1 to AC-6) were tested
for human SERT affinity in single point, in vitro binding assays. VS compounds were
assessed for their ability to displace 10 nM [3H]-paroxetine from the SERT in membrane
homogenates of HEK293 cells expressing human SERT. VS compounds were screened
at a single concentration of 10 μM (1000-fold molar excess relative to radioligand).
Figure 4.2 shows that all compounds did not significantly displace the binding of
radiolabeled ligand from the hSERT in membrane homogenates (Student‘s t-test,
p>0.05), indicating no hSERT affinity. The positive control SSRI sertraline (10 μM) was
used to assess non–specific radioligand binding, reducing [3H]-paroxetine binding by
778% (p<0.05).
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Figure 4.2.

VS hit compound one-point screening assay at hSERT. Membrane

homogenates of HEK-293 cells, stably transfected with hSERT, were used in the binding
assay. hSERT binding affinities were obtained by displacement of [ 3H] paroxetine. All
VS compounds were added at a final concentration of 10 μM. To measure non-specific
binding, 10 μM sertraline was used. * p < 0.05
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4.3 hDAT
The six VS hits attained from computational studies (AC-1 to AC-6) were tested
for human DAT affinity in single point in vitro binding assays.

Compounds were

assessed for their ability to displace 10 nM [3H]-WIN 35,428 in N2A-hDAT whole-cell
ligand binding assays. VS compounds were screened at a single concentration of 10 μM
(1000-fold molar excess relative to radioligand).
As shown in Figure 4.3, compound AC-1 displayed a trend of 15% inhibition of
[3H]-WIN binding, although this was not statistically significant based on the Student‘s ttest (p=0.13). None of the other compounds showed any significant displacement of the
radiolabeled ligand in whole cells (Student‘s t-test, p>0.05), indicating no hDAT affinity.
In a control experiment, 10 μM mazindol inhibited the binding of [3H]-WIN to DAT by
837% (p<0.05).

78

*

Figure 4.3. VS hit compound one-point screening assay at hDAT. Whole cells of
stably transfected hDAT-N2A cell line were used. hDAT binding affinities were obtained
by displacement of [3H]-WIN 35,428.

All VS compounds were added at a final

concentration of 10 μM. To measure non-specific binding, 10 μM mazindol was used.
* p < 0.05
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Chapter 5. Discussion and Future Directions

5.1 Pharmacophore-based Drug Design
The pharmacophore is a valuable concept in rational drug design, defining active
molecules that possess particular chemical features and geometry favoring the binding at
a specific target (Marriott et al., 1999).

However, despite the simplicity of

pharmacophoric representations they cannot fully explain the biophysical nature of
ligand-protein interactions (Seidel et al., 2010). As such, in the current study, out of the
over 800 compounds in the hit database and of the six screened compounds, none showed
any significant inhibition at any of the MATs. This is not a surprising result given that
the percentage of ―hit‖ compounds found from pharmacophore modeling and virtual
screening is typically less than 1% of all compounds screened (Bailey and Brown, 2001;
Schneider and Bohm, 2002).
In the present investigation, pharmacophore-based drug design was used to search
for novel NET inhibitors. With this method, several problems always arise: How/where
to set the boundary between active and inactive compounds? How many so-called false
positives (biologically inactive compounds falsely disguised as active compounds by
matching model features) were present in the hit list, and how many false negatives
(compounds not matched by pharmacophore query but are able to cause biological
activity) were missed in the virtual screen, if only a subset of retrieved hit compounds
was tested? (Langer, 2010). The answer to these questions is generally subjective in that
each computational biologist may have a different response to such challenges.
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An advantage of using a simple pharmacophore model is that it can lead to the
discovery of novel lead compounds possessing great structural diversity. For example,
each of the six synthesized reagents chosen for pharmacological screening is unique in
structural scaffold. Conversely, a potential disadvantage in pharmacophore-based drug
design is that because many compounds will be identiﬁed as ―hits‖, there is disagreement
as to which criteria to use in selecting compounds for pharmacological testing. In short,
there is still much room for research aimed at the improvement of pharmacophore-based
methods (Langer, 2010).
In this chapter, a variety of factors affecting the creation of the pharmacophore
model, the ranking mechanism of hit compounds and finally, the quality of retrieved hits
attained from the virtual screen will be discussed.

5.2 Choosing Training Set Compounds
A challenge lies in the seemingly simple procedure of selecting proper
compounds to comprise the training set. In order to avoid analog bias, in which the
pharmacophore model tends ignore all compounds different from the single scaffold from
which it has been derived, it is important to choose structurally diverse training set
compounds. The four training set compounds used in this study were carefully chosen
such that they would each be structurally-dissimilar: mazindol, milnacipran, reboxetine
and ―8d‖. Their IUPAC names are listed in Table 5.1
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Table 5.1. The four training set compounds and their IUPAC names.
Compound

IUPAC Name

Mazindol

(±)-5-(4-chlorophenyl)-3,5-dihydro-2H-imidazo[2,1-a]isoindol-5-ol

8d

3R-(3-fluoro-4-methylphenyl)nortropane-2-carboxylic acid methyl ester
(Carroll 2005).

Reboxetine

(R*,R*)-2-[(2-ethoxyphenoxy)-phenyl-methyl]morpholine

Milnacipran (1R*,2S*)-2-(aminomethyl)-N,N-diethyl-1phenylcyclopropanecarboxamide
Please refer to Table 3.1 for structures.

As can be examined from the names of these compounds, each is of a different
chemical scaffold. For example, mazindol contains the ―isoindole‖ group; compound 8d
has a tropane moiety; reboxetine contains the morpholine structure; and milnacipran has a
cyclopropane carboxamide group.

5.3 Pharmacophore Features

5.3.1 Choosing the Optimal Alignment based on Pharmacophore
Features
The alignment in the present study was chosen based on the features MOE
developed. A general rule for choosing the features in this investigation was the ―one
group—one type‖ policy (Horvath, 2011), meaning that a pharmacophore feature should
contain one chemical feature such as ―Donor‖ or ―Hydrophobic‖, rather than a ―one
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group—many types‖ policy such as a ―Donor / Hydrophobic‖ group.

The type of

chemical features might differ between two queries, but the most specific feature is
generally favored (Triballeu et al., 2006). In the current study, when an aromatic ring
was deemed an ―Aromatic / Hydrophobic‖ group, it was refined to be more specific as an
―Aromatic‖ group.
Moreover, based on the observations of Hovarth, no two authors ever came up
with the same set of pharmacophoric queries. While some authors allow atoms to carry
more than one pharmacophore ―flag‖ (such as a carboxylate group being both an ―anion‖
and a ―hydrogen bond acceptor‖), others limit a chemical group to one pharmacophore
type (Horvath, 2011). Sanders and colleagues asserted that in order to obtain an optimal
binding mode, it is important to select only those features that correlate, or are believed to
correlate, with biological activity (Sanders et al., 2012b). Although simply stated, it is
quite a difficult task to carry out.

5.3.2 External Volumes
The selectivity of pharmacophores can also be increased by the addition of shape
restraints (Sanders et al., 2012b). Greenidge et al. (1998) showed that the number of false
positives could be decreased by a factor of 2–5 with the addition of a shape restraint,
while the number of true positives remained nearly unchanged. Using a shape restraint
often ensures that molecules with many interacting groups can only match the
pharmacophore features in a conformation that is complementary to the protein binding
site (Sanders et al., 2012b). The generated model in this study included an exterior
volume feature in order to make the virtual screen more restrictive. After the addition of

83

the shape restraint, there was a general reduction in the number of retrieved hits from the
virtual screen. Further, when an exterior volume was added in the refinement/validation
process the number of inactive compounds retrieved were reduced from three to two.

5.4 Validation Test Set
When choosing compounds to comprise the test set, an important point to
consider is that they should be chemically different from those comprising the training
set. The problem lies in defining ―diverse‖. If the molecules of the training set are too
similar to those of the test set, this aspect of the validation is not very challenging for the
model; conversely, if they are too different, there is a risk of depriving the training set of
some key SAR (structure activity relation) information. Therefore, molecules kept for
the test set should be neither too similar nor too different from training set compounds
(Triballeu et al., 2006).
In the present study, the ten compounds comprising the test set (listed in Table 5.2
according to their IUPAC names) were structurally different from the training set
compounds, with the exception of compound ―3‖, a reboxetine analog.

Because

reboxetine was part of the training set, there is little diversity between it and ―3‖ (Figure
5.1). Based on the above assertion of Triballeau and colleagues, including structurally
similar compounds between the training set and the test set may not challenge the model,
causing a bias for a particular chemical scaffold and therefore lead to improper
validation. If a compound other than the reboxetine analog had been included in the test
set, it is likely that different feature characteristics would have evolved from the
refinement step, and different hit compounds would have been retrieved.
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Conversely,

the chemical structures of the training and active test set compounds did not differ greatly
as each molecule represents a NET inhibitor and there was no structural information lost.
In other words, because the training set compounds were not completely unrelated in
terms of structural scaffold, MOE was capable of finding common pharmacophore
features among the four compounds without missing a particular chemical moiety.

Table 5.2. IUPAC names of test set compounds. Ten test set compounds included five
high-affinity NET inhibitors (atomoxetine, duloxetine, nisoxetine, paroxetine, reboxetine
analog ―3‖) and low-affinity compounds at NET (bupropion, citalopram, sertraline,
venlafaxine, zimelidine).

Compound

IUPAC Name

Atomoxetine

(3R)-N-methyl-3-(2-methylphenoxy)-3-phenylpropan-1-amine; (R)-Nmethyl-3-phenyl-3-(o-tolyloxy)propan-1-amine
(+)-(S)-N-Methyl-3-(naphthalen-1-yloxy)-3-(thiophen-2-yl)propan-1amine
(RS)-3-(2-methoxyphenoxy)-N-methyl-3-phenylpropan-1-amine

Duloxetine
Nisoxetine
Paroxetine
―3‖

(3S,4R)-3-[(2H-1,3-benzodioxol-5-yloxy)methyl]-4-(4fluorophenyl)piperidine
2-([(2-methoxyphenyl)sylfanyl](phenyl)methyl)morpholine

Bupropion

(±)-2-(tert-Butylamino)-1-(3-chlorophenyl)propan-1-one

Citalopram

(RS)-1-[3-(dimethylamino)propyl]-1(4-fluorophenyl)-1,3-dihydroisobenzofuran-5-carbonitrile

Sertraline
Venlafaxine

(1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4tetrahydronaphthalen-1-amine
(RS)-1-[2-dimethylamino-1-(4-methoxyphenyl)-ethyl]cyclohexanol

Zimelidine

Z-3-(4-bromophenyl)-N,N-dimethyl-3-(pyridin-3-yl)prop-2-en-1-amine
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Reboxetine

Reboxetine Analog, Compound “3”

Figure 5.1. Comparison of the structures of reboxetine and its analogue, compound
“3”. Both compounds have the morpholine moiety (green circles). Compound ―3‖ has a
thiol group in the place of the oxygen in reboxetine (red squares), and a methylbenzyl
moiety replaces the ethylbenzyl moiety.
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5.5 Influence of pKa on Pharmacophore Features
A source of pharmacophore error is the presence of several ionizable groups
within one molecule, which could influence each other‘s pKa values (Horvath, 2011).
The recent development of a pharmacophore flagging approach based on calculated
predictions of pKa values of ionizable groups showed that some structurally similar
compounds with diverging activities may be explained by subtle changes in pKa values
of ionizable groups (Horvath, 2011) and could ultimately lead to significant changes in
acidic/basic species of hit compounds. It is worth noting that in this study the alignment
of the four training set compounds revealed the presence of either a donor or acceptor
group; choosing one feature over the other was by trial-and-error. The pharmacophore
center containing either an acceptor group or a donor group was changed in accordance to
the relative number of active and inactive compounds that were retrieved from the test set
database. Yet, it would certainly be appealing if a software feature were able to calculate
an approximate pKa at these centers, creating a fundamental method for defining how to
label a particular pharmacophore group – acceptor, donor, or just ―ionizable‖.

5.6 Virtual Screening

5.6.1 ZINC Database
In the current study, the ZINC database was used to screen for compounds
matching the pharmacophore query. An advantage of using the ZINC database is that it
is comprised of over 20 million purchasable compounds from over 150 vendors and
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represents the largest database of commercially available compounds for virtual
screening (VS). However, a consequence of screening such an extensive molecular
database is encountering irrelevant molecules. Despite this disadvantage, the creator of
the database, John Irwin, believes that in order to be relevant for research, a database for
ligand discovery should be big, and the compounds purchasable and biologically
appropriate (i.e., able to bind to the target structure) (Irwin et al., 2012). Further, the aim
of the virtual screen is to decrease the enormous number of small molecule candidates to
a manageable number of compounds that have the greatest chance of modulating a
particular protein target (Tondi et al., 1999). Based on the above assertions, ZINC
performs these functions and was deemed an adequate database for use in this
investigation.

5.7 Ranking of Hit Compounds

5.7.1 RMSD versus Overlay Methods
In this study an alignment-based (or overlay) method was used to rank hit
compounds. Scoring functions are divided into two classes, RMSD-based and overlaybased (Sanders et al., 2012a). In the RMSD-based method, the distance between the
feature group of a hit compound and the pharmacophore feature center is calculated.
Overlay-based approaches measure how the radii of the pharmacophore features match
(or overlay) to the atoms/centers of hit compounds (known as the ―S‖ score).
Conversely, RMSD scoring does not consider the feature radii (Sanders et al., 2012a).
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While RMSD-based approaches generally return hits due to the high number of
poses, overlay-based methods provide the more appropriate biophysical binding mode of
hit compounds. Moreover, the stricter criteria of overlay-based methods retrieve the
more relevant compounds, as this approach is better at discriminating between active and
inactive compounds (Sanders et al., 2012a). Choosing which ranking technique to use for
evaluating hit compounds was an area of uncertainty in this project. After conducting
searches through the literature, the overlay approach was determined to be the better
alternative.

5.7.2 Strain Energy versus Overlay Methods
Another approach to ranking hit compounds involves using strain energy. Here,
based on visual inspection, it was found that compounds with strain energies greater than
4 kcal/mol deviated from the alignment of the training set compounds. Thus, during the
conformational sampling process all compounds containing strain energies greater than 4
kcal/mol were discarded. Strain energy and the degree of overlap are often conflicting
parameters given that energetically-implausible geometric deformations may ultimately
align exactly two compounds containing pharmacologically similar groups (Hovarth,
2011). In this work, by discarding compounds with large strain energies, hits containing
these geometrical deformations may have been avoided.

Therefore, ranking hit

compounds based on strain energies could be another useful parameter, with the
compounds containing the most favorable strain energies chosen for pharmacological
assessment. Although in this study compounds were chosen based on their overlay
scores, strain energy is certainly an important ranking criterion.
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On the other hand, setting the threshold for which energy values are unacceptable
in the screening process is an indefinite approach. Like many other criteria to be decided
on in pharmacological-based screening, choosing where to set the limit for acceptable
strain energies is subjective and at the discretion of the computational chemist.

5.7.3 Clustering by Chemical Scaffold
Organizing molecules by their chemical scaffolds is another technique for ranking
hit compounds. Although in this study maximal overlay with the alignment of the
training set compounds was used to sort hits, an interesting approach known as clustering
could also have been taken into consideration. If the hit compounds are only analogs of
one scaffold and are structurally similar to known biologically active molecules, the
results of the virtual screen will not be of interest for further drug development.
Clustering of compounds with respect to scaffold represents another important tool for
organizing the hit list (Markt et al., 2011). In summary, it appears that a combination of
such approaches are likely to result in more diverse active compounds (Sanders et al.,
2012b).

5.8 Future Directions

5.8.1 Altering the Training Set
Although none of the purchased six reagents showed any significant activity, only
compound AC-1 displayed detectable inhibition of the dopamine transporter (~15%).
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This result suggests that the created pharmacophore model, if slightly refined, may prove
to be useful in the discovery of active MAT inhibitors. One approach would be to alter
the original training set. Perhaps different compounds may generate models consisting of
different pharmacophore features. A suggestion for future work would be to choose
compounds based on their selectivity at the MATs.

5.8.2 NET-selective TS Compounds
Compound 8d shows a preference for NET but is also quite potent at the other
MATs. Similarly, mazindol, though known as a norepinephrine reuptake inhibitor (Kim
et al., 2009), is only about 2.5 times more NET-selective relative to SERT and DAT.
Milnacipran is NET and SERT selective, with no appreciable DAT activity. Conversely,
reboxetine can be considered NET-specific (Table 5.3). Therefore, future directions
could entail replacing the training set compounds milnacipran, mazindol and 8d with
ligands of greater NET-selectivity.
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Table 5.3. MAT binding affinities of training set compounds, and the selectivity of
each compound relative to NET. Based on literature accounts, the selectivity of each
NET inhibitor is shown with SERT relative to NET and DAT relative to NET.
Binding Affinity, Ki (nM)

Selectivity Ratio

Compound

hDAT

hSERT

hNET

SERT/NET

DAT/NET

1: Mazindol

45±1

50±15

18±2

2.8

2.5

2: Milnacipran

>100,000

8.44±1.57

22±2.58

0.4

4545.5

3: Reboxetine

>10,000

440

11

40

909.1

4: 8d

9.0±2.5*

23.8±4.4

0.43±0.02

55.3

N/A

* Values represent IC50 (nM) affinities
1: Houlihan 2002
2: Vaishnavi 2004
3: Bymaster 2002
4: Carroll 2005
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5.8.3 Examining Analogs of AC-1
In order to examine whether modest structural modification of the hit compound
AC-1 would show greater inhibition at any of the MATs, analogs were built in MOE and
ranked according to their ―S‖ scores. Fifteen AC-1 analogs were created (Table 5.4), and
conformers for each were generated. The ―S‖ score was calculated for these compounds
relative to the original training set molecules. As a result, the structure of the original
AC-1 compound exhibited the best ―S‖ score compared to the analogs. Table 5.5 shows
all AC-1 analogs with an ―S‖ score of -114 or less. Although none of the AC-1 analogs
exhibited a better ―S‖ score than the original compound, this could be a useful method in
studying how altering structural substituents can change a particular score and possibly
lead to a different percent inhibition at a protein target.

93

Table 5.4. Analogs of compound AC-1. Analogs were created computationally and
assessed for their overlay scores.
AC-1 Analogs

AC-1

AC-10

AC-11

AC-12

AC-13

AC-14

AC-15

AC-16

AC-17

AC-18

AC-19

AC-20

AC-21
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AC-22

AC-23

Table 5.5. Analogs of AC-1 with an “S” score better than -114.
Structure

―S‖ Score

AC-1
-116

AC-10

-116

AC-11

-116

AC-12
-115
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AC-13
-115

AC-14
-115

AC-15
-115

5.8.4 Amine groups in CNS Drugs
The majority of CNS-active drugs tend to have a basic nitrogen located
approximately 5 Å from an aromatic ring (Guner, 2005). It was, therefore, interesting to
examine the distances between the same features of the model in the present
investigation. To measure the distances, the AC-1 analog AC-10 was aligned with the
refined pharmacophore query (Figure 5.2). The rationale for using AC-10 rather than
AC-1 was that because the methoxy group of AC-1 was changed to a methylamine group
to become compound AC-10, it was important to understand where the donor group
would position itself on AC-10. Alteration of the methoxy group did not change the
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orientation of the donor group, which remained aligned with the isoquinolinol hydroxyl
group. Despite this, based on Figure 5.2, the distances between the aromatic groups and
the donor group are approximately 5 Å, or 5.67 Å and 4.27 Å to be exact. If the alcohol
group were to be converted to an amine, it would meet the above criterion: to contain a
basic nitrogen about 5 Å from an aromatic feature. In Table 1, it could be detected that
such a structure was created, but because its ―S‖ score value was lower than expected, it
was not considered. In view of the fact that the ―S‖ score is not an exact measure of
activity, future directions could certainly entail synthesizing such an analog and testing it
in vitro at the MATs.
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Figure 5.2. Compound AC-10 demonstrating the distances in Angstroms from the
donor feature to the two aromatic features. The distance from the donor group to the
F2 aromatic group is 5.67 Å; the distance from the donor group to the F6 aromatic group
is 4.27 Å. Both values are close to 5 Å, indicating that if the alcohol group in the
isoquinolinol moiety were to be converted to a basic amine, there is great potential for
this compound to be active at the MATs.

98

5.8.5 Revision to Pharmacophore Model
Because the synthesized compounds (AC-1 – AC-6) did not show any significant
inhibition at any of the MATs, it was interesting to examine what effect altering the
pharmacophore model would have on the hit compounds.

As mentioned in the

computational chapter, a validation test set containing five active and five inactive
compounds at the NET was used to confirm that the created model was functional. The
generated model selected all five actives and one inactive, sertraline. Yet, there was no
internal validation performed. With internal validation a database of compounds is
created containing conformations of the original training set compounds. Therefore, this
approach examines whether a pharmacophore model could pick out training set
compounds. The model selected only one training set compound. This is a logical
outcome given that the pharmacophore features were based on the alignment of the
training set compounds but were refined from their original states.

Thus, it was

interesting to explore which features were necessary to return to their original forms in
order to retrieve all four training set compounds.
As in the previous query modification, each feature was systematically altered one
at a time until the original compounds were returned. The first step involved changing
the aromatic feature (the larger of the two aromatic features) back to its original form,
―Aro|Hyd‖. From this change, milnacipran and reboxetine were selected. Therefore, this
change was retained. Two more of the TS compounds still needed to be retrieved:
reboxetine and 8d. Changing the radius of the 0.89 Å ―Aro|Hyd‖ feature back to the
original 1.55 Å did not increase the number of retrieved TS compounds, so the radius was
returned to 0.89 Å. Both of the PiN features were then included one at a time, which did
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not retrieve any of the TS compounds, and were again removed. The hydrophobic
feature was then changed back from its small radius of 0.55 Å to 1.41 Å.

This

modification produced no change, as milnacipran and reboxetine were still the only two
training set compounds retrieved.
When the exterior volume feature was ignored, milnacipran and reboxetine were
again selected, but not mazindol or 8d. As changing the ―Aro‖ back to ―Aro|Hyd‖
produced the effect of retrieving milnacipran and reboxetine, the exterior volume
remained part of the model.
The next step was to vary the donor feature, which was initially an acceptor
feature. Switching ―Don‖ to ―Acc‖ retrieved two of the TS compounds, only this time
reboxetine and mazindol were retrieved. Thus, this change was implemented. Next, it
was interesting to revisit previous alterations, but with the acceptor feature replacing the
donor feature. When the hydrophobic feature radius was changed back to its original
1.41 Å, all of the TS compounds were selected.
As a result, it was necessary for three features to be returned to their original state:
the ―Aro‖ feature previously found between the PiNs was changed back to ―Aro|Hyd‖,
the ―Hyd‖ feature radius was again 1.41 Å, and the ―Don‖ feature was changed back to
―Acc‖.

These changes also retrieved one active compound (#3) and two inactives

(venlafaxine and zimelidine).

For future work, some additional refinement may be

necessary for the model in order for it to select more active and less inactive compounds,
while still selecting all four TS compounds.
From these results, it appeared as if the hydrophobic feature was a major factor
contributing to which TS compounds were retrieved. Small increments of change to its
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radius were experimented with to determine which test set compounds would be selected.
It was found that decreasing the ―Hyd‖ radius to 1 Å from 1.41 Å retrieved all four TS
compounds: one active compound (3), and this time, only one inactive (venlafaxine). But
considering that venlafaxine is moderately inactive at NET (approximately 3 M;
(Tsuruda et al., 2010)), it was deemed acceptable that the new ―semirefined‖ model
selected it. The new model is illustrated in Figure 5.3.
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Figure 5.3. Semi-refined model. Several features were restored to the original model in
such a way that the original training set compounds would be selected. The aromatic
(Aro) as well as the aromatic / hydrophobic (Aro|Hyd) features are both shown in orange;
the hydrophobic (Hyd) feature is shown in green; the acceptor (Acc) feature is shown in
cyan. The exterior volume is represented by gray netting around the accessible area of
the training set compounds (not shown).
pharmacophore annotation points.
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The small gray spheres represent

A comparison of the three models including the original pharmacophore query,
the refined query and the ―semi-refined‖ query, described above, is shown in Figure 5.4.
The features in the original pharmacophore query (Figure 5.4a) were refined to create the
―refined query‖ (Figure 5.4b) by changing several pharmacophore features.

The

―Aro|Hyd‖ features was changed to ―Aro‖ features. The radius was decreased from 1.55
Å to 1.00 Å and from 0.89 Å to 0.78 Å in the F6 ―Aro|Hyd‖ and F2 ―Aro|Hyd‖ features,
respectively. The PiN features became ignored in the refined query; the ―Hyd‖ feature
radius was decreased from 1.41 Å to 0.55 Å; the acceptor feature was amended to
become a donor feature and its radius decreased from 0.91 Å to 0.80 Å. An exterior
volume feature was also added to the refined query (shown in Figure 3.4) with a radius of
2.14 Å.
Several features in the refined query were returned to their original states,
generating the semi-refined query (Figure 5.4c). Feature F2 was changed from ―Aro‖ in
the refined query (Figure 5.4b) back to ―Aro|Hyd‖ while keeping the radius constant; the
―Hyd‖ feature radius was increased from 0.55 Å to become 1.00 Å; the ―Don‖ feature
and its radius was changed back to its original state to become ―Acc‖ with a radius of
0.91 Å; the exterior volume and its radius were not changed.
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(a)

(b)

(c)

Figure 5.4. Comparison of three generated pharmacophore models. The original
query (a), refined query (b) and semi-refined query (c).
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5.8.6 Rescreening the ZINC Database
The ZINC database was rescreened with the newly-refined pharmacophore query,
and the ―S‖ score svl code was reentered into MOE in order to rank the new hits. This
time the score appeared to be better than for the previous screen. The numbers were
significantly smaller, with the best score being -120, compared to -116 seen with AC-1,
the best score attained in the previous screen. This time, all hits with an ―S‖ score greater
than -115 were discarded from the output database. As a result, there were 73 new hits
that appeared to overlay better to the original training set alignment than previously. The
top hits, with ―S‖ scores of -120 and -119 are shown in Table 5.6 and as overlays to the
original training set alignments in Figure 5.5. If visually compared to the AC-1 hit,
shown in Figure 5.6, compounds, AC-7 and AC-8, align significantly better to the
original training set alignment. Future research could include synthesizing these three
compounds and pharmacologically assessing them at the three MATs.
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Table 5.6.

Structures and “S” Scores of the top three new hit compounds.

Compounds AC-7, AC-8 and AC-9 were retrieved from a second virtual screen using the
semi-refined pharmacophore model.
Structure

―S‖ Score

AC-7
-120

AC-8
-119

AC-9
-119
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(a)

(b)

Figure 5.5. Overlay of top new hits from the semi-refined query to the alignment of
the original training set compounds. Compound AC-7, shown in orange (a), generated
an ―S‖ score of -120; compound AC-8, in cyan (b), produced an ―S‖ score of -119.
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Figure 5.6. Overlay of AC-1 to the original training set alignment. AC-1 is shown in
orange, with an ―S‖ score of -116. By visual inspection, it can be seen that AC-1 aligns
poorly to the training set compounds as compared to AC-7 and AC-8 (Figure 5.5).
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As another internal control to determine whether the deviations in ―S‖ score are
representative of good or poor overlays, it was interesting to examine what the worst ―S‖
score overlay would look like. Figure 5.7 illustrates the compound AC-0 with an ―S‖
score of -88 overlaid on the training set alignment. It is clear that there is a poor
correlation to the original alignment. From these results, it can be concluded that the
higher the ―S‖ score, the better the alignment and therefore, the more potential for a hit
compound to show activity at the NET.

109

Figure 5.7. Illustration of poorest alignment. Compound AC-0 has an ―S‖ score of 88 and is illustrated overlaying the training set alignment. It can be seen that there is a
generally poor alignment between AC-0 and the four active set compounds, and it is
defined by having a poor overlay score.
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5.8.7 Selecting Compounds Based on RMSD versus Overlay Score
Another approach for future work would be to choose several top-ranking
compounds having the best overlay, or ―S‖ score, as well as several compounds
exhibiting the best (or lowest) RMSD score for pharmacological studies. Rather than
solely choosing hits by their overlay score, as in this study, it may be possible to
determine which ranking criteria are most helpful in selecting compounds for competition
binding assays. Further, it may also be possible to select compounds based on the
combination of RMSD value and ―S‖ score. In the second virtual screen, all hits having
an ―S‖ score greater than -115 were discarded, leaving 73 compounds to choose from,
with scores ranging from -115.00 to -120 . Among these compounds the RMSD score
ranged from 0.299 Å to 0.751 Å. Given that all of these 73 compounds exhibited good
alignment to the training set compounds, it may be beneficial to choose compounds with
a relatively lower RMSD score. Interestingly, the top three hits (AC-7, AC-8 and AC-9)
all have relatively lower RMSD scores, ranging from 0.419 Å to 0.494 Å. Therefore,
these three compounds show great potential at inhibiting any of the MATs.

5.8.8 Unique structure of hit compounds
Heterocyclic compounds, particularly nitrogen heterocycles, are a valuable class
of compounds in the pharmaceutical industry and consist of about 60% of all drug
substances. In particular, the tetrahydroisoquinoline ring structure is a chemical scaffold
common to many biologically active natural products and pharmacologically relevant
therapeutic agents (Sridharan et al., 2011). The structures of AC-1, AC-8 and AC-9 all
contain the isoquinoline scaffold. Isoquinoline is one of the most broadly distributed
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alkaloids with established therapeutic benefit.

Their development as effective

therapeutics is an area of continued study (Bhadra and Kumar, 2011).

5.8.9 Refining the Structure of New Hit Compounds
Based on the review by Guner (2005) regarding active CNS drugs containing a
basic amine group located about 5 Å from an aromatic pharmacophore group, it may be
constructive to refine the structure of new hit compound AC-7 accordingly. As seen in
Figure 5.2 with compound AC-10, the distances from the aromatic groups to the donor
group (Figure 5.2) or the acceptor group (Figure 5.8) are the same given that the spatial
orientation of the pharmacophore features in the semirefined model were not changed. In
Figure 5.8, compound AC-7 is overlaid with the semirefined query. The acceptor group
is located on the carboxylic acid. However, if this substituent were to be replaced with a
basic amine group, it would be located ~ 5 Å from an aromatic group. Therefore, by
making structural changes to compound AC-7 it may lead to an active drug at the MATs.
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Figure 5.8. Compound AC-7 demonstrating the distances in Angstroms from the
acceptor feature to the two aromatic features. The distance from the acceptor group to
the F2 ―Aro|Hyd‖ group is 5.67 Å; the distance from the acceptor group to the F6
aromatic group is 4.27 Å. Both values are close to 5 Å, indicating that if the ester group
were to be converted to a basic amine, there is potential for this compound to be active at
the MATs.
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5.9 Conclusion
Computational chemistry and structural biology are playing a progressively more
significant role in drug discovery.

Pharmacophore-based drug design can present a

preliminary representation of the different aspects involved in the binding interactions
between a ligand and its receptor protein.

Using this information, chemists could

rationally design molecules with specific chemical characteristics necessary for the
proper interaction to a binding site (Wang and Lewis, 2010).

Yet, pharmacophore

modeling is not based on a fundamental theory, and, as such, is intrinsically error-prone
(Horvath, 2011). Despite the prosperity of pharmacophore techniques there is room for
improvement, such in the creation of more optimal pharmacophore models.
In regard to choosing the proper approach for the creation, alignment or ranking
of the pharmacophore model, the ―best‖ pharmacophore scheme is the one maximizing
the retrieval of active and minimizing the retrieval of inactive hit compounds. In the end,
it is less important to understand whether one method is slightly ―better‖ than another,
statistically speaking, rather which approach can lead to biologically relevant hits.
(Horvath, 2011).
In this investigation, although none of the tested hit compounds showed
significant inhibition at any of the MATs, the new hits attained with the ―semirefined‖
model show potential as novel MAT inhibitors since they have a better overall alignment
to the original training set compounds, as demonstrated by their higher overlay score.
Furthermore, using a combination of ranking criteria may prove to be beneficial in
selecting hit compounds from a pharmacophore-based virtual screening study. In the
present study, the new hits (AC-7 – AC-9) exhibit the best overlay to the original training
114

set compounds and also have relatively low RMSD values. Future directions could entail
synthesizing and evaluating compounds AC-7, AC-8 and AC-9 with in vitro
pharmacology, to attain their activity profiles at the monoamine transporters.
Considering the difficulties involved in attaining protein target information,
ligand-based drug design approaches are anticipated to have a significant impact on drug
design in the near future (Tropsha and Wang, 2006; Costanzi et al., 2009). In summary,
the pharmacophore concept has truly stood the test of time and is likely to play an
important role in drug development for years to come (Langer, 2010).
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